Overview First in Human, Single Ascending Dose Study Status: Completed Trial end date: 2022-08-31 Target enrollment: Participant gender: Summary The goal of this study is to evaluate the safety and tolerability of single ascending oral doses of INV-101 in healthy adult subjects. Phase: Phase 1 Details Lead Sponsor: Innovo Therapeutics, Inc.